Elsevier

Biochemical Pharmacology

Volume 37, Issue 3, 1 February 1988, Pages 389-394
Biochemical Pharmacology

Inhibition of phagocyte chemotaxis by uteroglobin, an inhibitor of blastocyst rejection

https://doi.org/10.1016/0006-2952(88)90204-3Get rights and content

Abstract

Uteroglobin, a steroid-dependent secretory protein first discovered in the rabbit uterus during early pregnancy, is a potent phospholipase A2 inhibitor. We found that uteroglobin also inhibited human and rabbit phagocyte chemotaxis in response to formyl peptide attractants in a dose-dependent manner. Half-maximal inhibition was at 1.2 μM. Uteroglobin did not compete with a formyl peptide for its receptor but inhibited internalization of radiolabeled formyl peptide. Uterglobin appears to inhibit chemotaxis by a mechanism different from that of dansylcadaverine, a well studied inhibitor of endocytosis. Unlike dansylcadaverine, uteroglobin did not have any effect upon the synthesis of phosphatidylcholine or phosphatidylinositol. It is suggested that uteroglobin may protect trophoblastic cells from the defense system of the host not only by binding to antigenic determinants of embryonic cells but also by impairing migration of phagocytes, one of the primary components of the immune defense system. These results may explain why embryonic cells do not elicit an inflammatory response in the uterine endometrium during pregnancy.

References (35)

  • A.B. Mukherjee et al.

    Med. Hypotheses

    (1980)
  • H.M. Beier

    Biochim. biophys. Acta

    (1968)
  • W.A. Marasco et al.

    J. biol. Chem.

    (1984)
  • J.E. Folk et al.

    Adv. Protein Chem.

    (1977)
  • L. Harvath et al.

    J. Immun. Meth.

    (1980)
  • S. Aswanikumar et al.

    Biochem. biophys. Res. Commun.

    (1977)
  • R. Manjunath et al.

    Biochem. biophys. Res. Commun.

    (1984)
  • T.J. Higgins et al.

    Biochem. biophys. Res. Commun.

    (1980)
  • B.D. Cowan et al.

    Fert. Steril.

    (1986)
  • S.W. Levin et al.

    Life. Sci.

    (1986)
  • A.E. Beer et al.

    J. exp. Med.

    (1972)
  • A.E. Beer et al.
  • R.S. Krishnan et al.

    Science

    (1967)
  • A.B. Mukherjee et al.

    Am. J. reprod. Immun.

    (1982)
  • H.J. Showell et al.

    J. exp. Med.

    (1976)
  • F. Hirata et al.
  • V.F. Leuven et al.

    Cell

    (1980)
  • Cited by (85)

    • Modulators of inflammation in Bronchopulmonary Dysplasia

      2018, Seminars in Perinatology
      Citation Excerpt :

      A number of alternate approaches have been explored, including co-administration of piperine to enhance bioavailability, and the development of nanoparticle delivery devices.106,107 CC10, also known as uteroglobin, is a 10kDa homodimeric secretory protein produced by Clara cells in the airways and in the urogenital tract, This protein possesses a number of in vitro anti-inflammatory properties including blocking of N-Formyl-methionyl-leucyl—phenylalanine (fLMP)-stimulated neutrophil and monocyte chemotaxis,108 inhibition of phospholipase A2 (PLA2),109 inhibition of platelet aggregation,110 and suppression of IL2-stimulated production of tumor necrosis factor alpha (TNFα), IL1ß and interferon (IFN)γ in lymphocytes.111 CC10 knockout mice exposed to hyperoxia,112,113 or ozone,114 demonstrate an increased inflammatory response consisting of an exaggerated pro-inflammatory cytokine profile including IL1ß and an accumulation of inflammatory cells.

    • Relation between circulating CC16 concentrations, lung function, and development of chronic obstructive pulmonary disease across the lifespan: A prospective study

      2015, The Lancet Respiratory Medicine
      Citation Excerpt :

      Some animal studies also indicate increased susceptibility of knockout mice to COPD-related phenotypes in response to cigarette smoking,34,35 although one study failed to find an increased risk of emphysema.17 Results from in-vitro studies suggest that CC16 affects inflammatory cell function36,37 and that these effects might be linked to inhibition of PLA2 activity,38 expression of prostaglandins,39 chemotaxis,36,40 and cytokine production.37,41 Although this study supports the temporal relation of CC16 concentrations and subsequent lung health outcomes, the possible relevance of this biomarker in the clinical or public health setting needs to be determined.

    • Adjunctive pharmacotherapy in neonates with respiratory failure

      2009, Seminars in Fetal and Neonatal Medicine
      Citation Excerpt :

      Clara cell protein (CC10) is a small secretory protein that is present in abundance in the respiratory tract where it is produced mainly by Clara cells in the lung.99 It is a potent anti-inflammatory agent inhibiting neutrophil chemotaxis and a variety of pro-inflammatory cytokines.100,101 A randomised controlled study on ventilated preterm infants with respiratory distress syndrome showed that intra-tracheal recombinant human CC10 (rhCC10) was well-tolerated and significantly reduced the amount of inflammatory markers in tracheal aspirate.102

    View all citing articles on Scopus
    View full text